Field cancerization therapy with ingenol mebutate contributes to restoring skin-metabolism to normal-state in patients with actinic keratosis: a metabolomic analysis
Rattachement africain : it. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Actinic keratosis (AK) is a skin premalignant lesion, which progresses into squamous cell carcinoma (SCC) if left untreated. Ingenol mebutate gel is approved for local treatment of non-hyperkeratotic, non-hypertrophic AK; it also has the potential to act as a field cancerization therapy to prevent the progression of AK to SCC. To gain better insights into the mechanisms of ingenol mebutate beyond the mere clinical assessment, we investigated, for the first time, the metabolome of skin tissues from patients with AK, before and after ingenol mebutate treatment, with high-resolution magic angle spinning nuclear magnetic resonance spectroscopy. The metabolomic profiles were compared with those of tissues from healthy volunteers. Overall, we identified a number of metabolites, the homeostasis of which became altered during the process of tumorigenesis from healthy skin to AK, and was restored, at least partially, by ingenol mebutate therapy. These metabolites may help to attain a better understanding of keratinocyte metabolism and to unmask the metabolic pathways related to cell proliferation. These results provide helpful information to identify biomarkers with prognostic and therapeutic significance in AK, and suggest that field cancerization therapy with ingenol mebutate may contribute to restore skin metabolism to a normal state in patients with AK.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Field cancerization therapy with ingenol mebutate contributes to restoring skin-metabolism to normal-state in patients with actinic keratosis: a metabolomic analysis
- Date Crossref
- 08/08/2019
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of Bologna pays non établi dans la noticeUniversité ou école supérieure
-
University of Modena and Reggio Emilia pays non établi dans la noticeUniversité ou école supérieure
-
Dipartimento di Scienze per la Qualità della Vita pays non établi dans la noticeInstitution
-
Dipartimento Chirurgico pays non établi dans la noticeInstitution
-
Dipartimento di Scienze Chimiche e Geologiche pays non établi dans la noticeInstitution
-
Centro Interdipartimentale Grandi Strumenti pays non établi dans la noticeInstitution
University of Bologna, University of Modena and Reggio Emilia et Dipartimento di Scienze per la Qualità della Vita, avec 3 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.